ADAM HIGGINS

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act. S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.

Policy issues relating to transparency and conflicts of interest in the financial services' proxy advisory industry, and capital markets structure. H.R. 1839, the "Reforming Access for Investments in Startup Enterprises Act."

Policy issues relating to transparency and conflicts of interest in the financial services' proxy advisory industry, and capital markets structure. H.R. 1839, the "Reforming Access for Investments in Startup Enterprises Act."

H.R. 2146, the "Trade Preferences Extension Act." Policy issues relating to the Trans-Pacific Partnership trade agreement.

H.R. 2146, the "Trade Preferences Extension Act." Policy issues relating to the Trans-Pacific Partnership trade agreement.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."

H.R. 3982, the "Family Cord Blood Banking Act." Policy issues relating to corporate tax reform.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.

H.R. 3982, the "Family Cord Blood Banking Act." Policy issues relating to corporate tax reform.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act." Policy issues relating Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. H.R. 6, the "21st Century Cures Act."

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. H.R. 6, the "21st Century Cures Act."

H.R. 6, the "21st Century Cures Act." Policy issues relating Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically Section 902 relating to the Breakthrough Therapy Designation for pharmaceuticals.

H.R. 6, the "21st Century Cures Act," specifically policy issues relating to combination pharmaceutical products.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act. S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."

H.R. 6, the "21st Century Cures Act," specifically policy issues relating to combination pharmaceutical products.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry.

S. 2012, the "Energy Policy Modernization Act." H.R. 8, the "North American Energy Security and Infrastructure Act."

S. 2012, the "Energy Policy Modernization Act." H.R. 8, the "North American Energy Security and Infrastructure Act."

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.

H.R. 9, the "Innovation Act," specifically those sections relating to amending the Inter Partes Review process.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act. S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act. S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the Family Cord Blood Banking Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases; patient cost-sharing for specialty medicines; and step therapy. H.R. 6, the "21st Century Cures Act. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 2841, the "Fair Access for Safe and Timely Generics Act." H.R. 1600, the "Patients' Access to Treatments Act." H.R. 2739, the "Cancer Drug Coverage Parity Act." S.1566, the "Cancer Drug Coverage Parity Act." H.R. 3982, the "Family Cord Blood Banking Act."

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act. S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

S. 2012, the "Energy Policy Modernization Act." H.R. 8, the "North American Energy Security and Infrastructure Act."

S. 2012, the "Energy Policy Modernization Act." H.R. 8, the "North American Energy Security and Infrastructure Act."

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act. S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the "Food and Drug Administration Safety Over Sequestration Act." H.R. 160, the"Protect Medical Innovation Act. S. 149, the "Medical Device Access and Innovation Protection Act." S. 1077, the "Advancing Breakthrough Devices for Patients Act." S. 1622, the "FDA Device Accountability Act." S. 2737, the "Improving Medical Device Innovation Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act." H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." S. 275, the "Medicare Home Infusion Site of Care Act." Policy issues relating to the Centers for Medicare and Medicare Services' Comprehensive Ambulatory Payment Classification.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. Policy issues relating to tax benefits for cord blood banking, placental blood banking and placental tissue banking services. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. Policy issues relating to federal tax benefits for cord blood banking, placental blood banking and placental tissue banking services. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act.

21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2, the "Medicare Access and CHIP Reauthorization Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues. Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.

21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. H.R. 2, the Medicare Access and CHIP Reauthorization Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

Electricity transmission and nuclear energy issues. H.R. 1558, the "Resolving Environmental and Grid Reliability Conflicts Act." S. 848, the "Resolving Environmental and Grid Reliability Conflicts Act."

Electricity transmission and nuclear energy issues. H.R. 1558, the "Resolving Environmental and Grid Reliability Conflicts Act." S. 848, the "Resolving Environmental and Grid Reliability Conflicts Act."

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. H.R. 2, the Medicare Access and CHIP Reauthorization Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 2020, the "Protecting Americans from Tax Hikes Act," specifically that section suspending the medical device excise tax. H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection.

H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program. Policy issues relating to Medicare coverage for prosthetic urological interventions, including H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients." Policy issues relating to a proposed FDA regulation on generic drug labeling. H.R. 6, the 21st Century Cures Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act.

H.R. 6, the "21st Century Cures Act," specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program. Policy issues relating to Medicare coverage for prosthetic urological interventions, including H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients." Policy issues relating to a proposed FDA regulation on generic drug labeling. H.R. 6, the 21st Century Cures Act. H.R. 160, the Protect Medical Innovation Act. S. 149, the Medical Device Access and Innovation Protection Act.

H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. Policy issues relating to federal tax benefits for cord blood banking, placental blood banking and placental tissue banking services. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. Policy issues relating to tax benefits for cord blood banking, placental blood banking and placental tissue banking services. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act.

Policy issues relating to transparency and conflicts of interest in the financial services' proxy advisory industry, and capital markets structure. H.R. 1839, the "Reforming Access for Investments in Startup Enterprises Act."

Financial services, including transparency and conflicts of interest in the proxy advisory industry, capital markets structure, and policy issues relating to SEC conflicts minerals regulation. H.R. 1839, the "Reforming Access for Investments in Startup Enterprises Act."

21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2, the "Medicare Access and CHIP Reauthorization Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues. Public Law No. 110-85, the "Food and Drug Administration Amendments Act," including current policy issues relating to FDA's Risk Evaluation and Mitigation Strategy authority.

H.Res. 106, "Supporting Quality of Life for Prostate Cancer Patients." H.R. 2, the "Medicare Access and CHIP Reauthorization Act. 21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry. Policy issues relating to a proposed FDA regulation on generic drug labeling. Policy issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program and the Medical Device User Free program.

Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the implementation of the Prescription Drug User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues. 21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry. H.R. 2, the Medicare Access and CHIP Reauthorization Act.

21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the biotechnology industry, and policies impacting antimicrobial product innovation. H.R. 512, the "Developing an Innovative Strategy for Antimicrobial Resistant Microorganisms Act." S. 145, the "Promise for Antibiotics and Therapeutics for Health Act." H.R. 2, the "Medicare Access and CHIP Reauthorization Act." S. 275, the "Medicare Home Infusion Site of Care Act." Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Prescription Drug User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," including policy and implementation issues.

21st Century Cures draft legislation, specifically those sections relating to regulatory and reimbursement policies affecting the medical technology industry. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 160, the Protect Medical Innovation Act. S.1 49, the Medical Device Access and Innovation Protection Act. H.R. 2, the Medicare Access and CHIP Reauthorization Act. Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to implementation of the Medical Device User Fee program. Public Law No. 111-148, the "Patient Protection and Affordable Care Act," specifically implementation issues regarding the medical device tax, accountable care organizations and the Sunshine Act.

H.R. 2020, the "Protecting Americans from Tax Hikes Act," specifically that section suspending the medical device excise tax. H.R. 160, the Protect Medical Innovation Act. S.149, the Medical Device Access and Innovation Protection Act. H.R. 880, the American Research and Competitiveness Act.

H.R. 2146, the "Trade Preferences Extension Act." Policy issues relating to the Trans-Pacific Partnership trade agreement.

H.R. 2146, the "Trade Preferences Extension Act."

H.R. 2146, the "Trade Preferences Extension Act."

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. Policy issues relating to tax benefits for cord blood banking, placental blood banking and placental tissue banking services. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act.

Policy and implementation issues relating to Public Law No. 111-148, the "Patient Protection and Affordable Care Act." Policy and implementation issues relating to Public Law No. 112-144, the "Food and Drug Administration Safety and Innovation Act," specifically those sections relating to the Prescription Drug User Fee program. Current policy issues relating to Public Law No. 110-85, the "Food and Drug Administration Amendments Act," specifically FDAs Risk Evaluation and Mitigation Strategy authority. Policy issues relating to orphan drugs, dormant therapies and medicines for rare diseases. Policy issues relating to patient cost-sharing for specialty medicines. H.R. 6, the 21st Century Cures Act. H.R. 1078, the Food and Drug Administration Safety Over Sequestration Act. H.R. 2841, the Fair Access for Safe and Timely Generics Act. H.R. 1600, the Patients Access to Treatments Act. H.R. 2739, the Cancer Drug Coverage Parity Act. H.R. 3982, the Family Cord Blood Banking Act.